Investor Relations

Overview
News & Events
Corporate Governance
Stock Information
Financials & Filings
- SEC Filings
Resources

News releases

Year

10 Jan / 23

Absci First to Create and Validate De Novo Antibodies with Zero-Shot Generative AI

This breakthrough unlocks the potential to accelerate time to clinic by over 50% and increase probability of success in the clinic Creating antibodies in silico with generative AI represents a major industry breakthrough on the path to fully de novo antibody design and Absci’s vision to deliver

08 Jan / 23

Absci to Participate in the 41st Annual J.P. Morgan Healthcare Conference

VANCOUVER, Wash. and NEW YORK, Jan. 08, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcoming 41 st Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

Pagination

First page
Previous page
Page 1
Page 2
Current page 3

Displaying 21 - 22 of 22

Featured Pages

Investor Tools

RSS Feeds
Print Page
Email Alerts
Contact IR

Request Email Alerts

Facebook
Twitter
LinkedIn
Google+

You’re leaving the Absci website. This link is provided for your convenience, but the content is the sole responsibility of its owner. Do you want to continue?

Return to the Absci website at any time by using the “Back” button on your web browser.

YES

NO